Computational Screening of CCR5 Inhibitors as Potential Entry Inhibitor Microbicides Using 3D-QSAR Studies, Docking and Molecular Dynamics Simulation

被引:0
作者
Ramachandran, Radhika [1 ]
Aathi, Muthusankar [2 ]
Ruban, Durairaj D. [1 ]
Piramanyagam, Shanmughavel [1 ]
机构
[1] Bharathiar Univ, Dept Bioinformat, Coimbatore 641046, Tamil Nadu, India
[2] Int Ctr Genet Engn & Biotechnol, Membrane Prot Biol Grp, Aruna Asaf Ali Marg, New Delhi 110067, India
关键词
CCR5; antagonists; docking; 3D-QSAR; microbicides; molecular dynamics; pharmacophore; ANTI-HIV ACTIVITY; RECEPTOR ANTAGONISTS; BIOLOGICAL EVALUATION; LEAD OPTIMIZATION; SIDE-CHAINS; 3D QSAR; DISCOVERY; SAR; DERIVATIVES; IDENTIFICATION;
D O I
10.2174/1570162X15666170106124216
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The chemokine receptor CCR5 acts as a co-receptor for HIV binding and it is considered as an important target by CCR5 antagonists. Entry inhibitor based microbicides gain much importance nowadays as these drugs act at an early stage of HIV lifecycle and thus hinder the viral replication process in humans. The present study intends to identify a CCR5 antagonist which could be developed as a microbicide using computational approaches. Methods: The pharmacophore modeling and 3D QSAR studies was used to screen CCR5 antagonists with enhanced antagonist activity. The docking studies ranked the compounds according to their bind- ing affinity and molecular dynamics simulation validated the stability of the enzyme-ligand complex. Results: A five point pharmacophore hypothesis HHPRR (2 hydrophobic; 1 positively ionisable; 2 aromatic ring) was generated. A statistically significant 3D QSAR model with 3 PLS factors was gen-erated for common pharmacophore hypothesis HHPRR. 3 with good correlation coefficient value (R-2=0.7483). The docking studies revealed that molecular interaction of CCR5 antagonists having good binding affinity are better than the microbicides taken for this study. The QSAR maps revealed the regions as a combined effect of hydrogen bond donors, hydrogen bond acceptors and hydrophobic groups which denoted the substitution of groups indicating the favorable and unfavorable regions for antagonist activity of hydroxypiperidine derivatives. The docking analysis and molecular dynamics simulation screened and validated CCR5 antagonists. Conclusion: The present study was successful in identifying a CCR5 antagonist which could be developed as a microbicide.
引用
收藏
页码:234 / 244
页数:11
相关论文
共 54 条
[1]   Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers [J].
Abraham, Mark James ;
Murtola, Teemu ;
Schulz, Roland ;
Páll, Szilárd ;
Smith, Jeremy C. ;
Hess, Berk ;
Lindah, Erik .
SoftwareX, 2015, 1-2 :19-25
[2]  
[Anonymous], GLID VERS 5 8
[3]  
[Anonymous], 2012, PROT PREP WIZ MAESTR
[4]  
[Anonymous], PHASE VERS 3 4
[5]  
Armour DR, 2000, Chem Abstr CA, V133, P89523, Patent No. 0038680
[6]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[7]  
Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5
[8]   Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of α-glucosidase inhibitors [J].
Bharatham, Kavitha ;
Bharatham, Nagakumar ;
Park, Ki Hun ;
Lee, Keun Woo .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2008, 26 (08) :1202-1212
[9]   Generation of predictive pharmacophore models for CCR5 antagonists: Study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors [J].
Debnath, AK .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (21) :4501-4515
[10]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732